Neurol. praxi. 2019;20(5):395-398 | DOI: 10.36290/neu.2019.147
Alemtuzumab treatment in multiple sclerosis: real clinical experience
- Neurologická klinika LF a FN Hradec Králové
Alemtuzumab (Lemtrada®) is a humanized monoclonal antibody indicated for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS), targeting the CD52 glycoprotein expressed on the surface of immune cells, mainly T and B lymphocytes. The precise action of alemtuzumab is unknown, but it is thought to involve binding with CD52 antigen that leads to depletion of circulating T and B cells resulting in development of new lymphocyte generation potentially without autoaggressive signs of the original population. Although the efficacy of alemtuzumab has been widely proven, several severe adverse effects have been reported with its use. In this paper we describe the first and successfully alemtuzumab-treated MS patient in our department.
Keywords: multiple sclerosis, treatment, alemtuzumab, autoimmunity
Published: November 1, 2019 Show citation
References
- CAMMS Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801.
Go to original source... 
Go to PubMed... - Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828. Go to original source... Go to PubMed...
- Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compton DA, CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012b; 380: 1829-1839. Go to original source... Go to PubMed...
- Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-17. Go to original source... Go to PubMed...
- Cuker A, Palmer J, Oyuela P, Margolin D, Bass A. Successful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis. Neurology 2014; 82: P2.198.
- Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014; 99: 80-89. Go to original source... Go to PubMed...
- Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol 2013; 4(4): 1000152. Go to original source...
- Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K. Switching patients at high risk of PML from natalizumab to another disease modifying therapy. Pract Neurol 2016; 16: 389-393. Go to original source... Go to PubMed...
- Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21: 22-34. Go to original source... Go to PubMed...
- Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8(1): 31-45. Go to original source... Go to PubMed...
- Jones JL, Thompson SA, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahley MT, Compston A, Coles AJ. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 2013; 110(50): 20200-20205. Go to original source... Go to PubMed...
- Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019; 12: 1756286419836571. Go to original source... Go to PubMed...
- Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7: 55-63. Go to original source... Go to PubMed...
- Miller JR. The importace of early diagnosis of multiple sclerosis. J Manag Care Pharm 2004; 10: S4-S11.
- Penkert H, Delbridge C, Wantia N, Wiestler B, Korn T. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol 2016; 73(6): 757-759. Go to original source... Go to PubMed...
- Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7(6): e39416. Go to original source... Go to PubMed...
- Rau D, Lang M, Harth A, Naumann M, Weber F, Hayrettin T, Bayas A. Listeria meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis - Report of Two Cases. Int J Mol Sci 2015; 16(7): 14669-14676. Go to original source... Go to PubMed...
- Thomas K, Eisele J, Rodriguez-Leal FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2016; 3: e228. Go to original source... Go to PubMed...
- Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P; Southern Italy MS Group. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. 2003; 9: 451-457. Go to original source... Go to PubMed...
- Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003; 61: 184-189. Go to original source... Go to PubMed...
- Willis MD, Robertson NP. Alemtuzumab for the treatment of multiple sclerosis. Ther Clin Risk Manag 2015; 11: 525-534. Go to original source... Go to PubMed...
- Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol 2013; 191: 5867-5874. Go to original source... Go to PubMed...
- Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017; 10(10): 343-359. Go to original source... Go to PubMed...